Crizotinib, an ATP-competitive small-molecule inhibitor of receptor tyrosine kinases C-Met, ALK, and ROS1, has shown significant efficacy in patients with advanced ALK-positive lung cancer (Shaw et al. 2020). This evidence concerns the gene ROS1 and lung cancer.